PURPOSE: Most neuroblastoma patients over 18 months of age at diagnosis present disseminated disease. The presence of neuroblastoma cells in bone marrow can be used to evaluate the response to treatment. It is possible that alterations in certain tumour cells might confer a selective advantage over tumour dissemination process, and probably be helpful in the clonal selection of tumour-specific cells that could originate metastasis. METHODS: We performed real-time quantitative PCR to identify the presence of disseminated tumour cells in bone marrow samples, and we used MSP to analyse the methylation profile of 20 genes putatively implied in dissemination. RESULTS: We described epigenetic alterations in the methylated status of certain genes in disseminated tumour cells from bone marrow. Those cases with high rate of hypermethylation showed an increased probability of relapse during or after treatment. We found significantly poor prognosis in event-free survival in cases with hypermethylation of TMS1, MGMT and RARbeta2 genes. CONCLUSION: We could not confirm the presence of a specific methylation profile in disseminated neuroblastoma tumour cells, but a high accumulation of epigenetic events in those cells is associated with a high risk of relapse, independently of MYCN amplification.
PURPOSE: Most neuroblastomapatients over 18 months of age at diagnosis present disseminated disease. The presence of neuroblastoma cells in bone marrow can be used to evaluate the response to treatment. It is possible that alterations in certain tumour cells might confer a selective advantage over tumour dissemination process, and probably be helpful in the clonal selection of tumour-specific cells that could originate metastasis. METHODS: We performed real-time quantitative PCR to identify the presence of disseminated tumour cells in bone marrow samples, and we used MSP to analyse the methylation profile of 20 genes putatively implied in dissemination. RESULTS: We described epigenetic alterations in the methylated status of certain genes in disseminated tumour cells from bone marrow. Those cases with high rate of hypermethylation showed an increased probability of relapse during or after treatment. We found significantly poor prognosis in event-free survival in cases with hypermethylation of TMS1, MGMT and RARbeta2 genes. CONCLUSION: We could not confirm the presence of a specific methylation profile in disseminated neuroblastoma tumour cells, but a high accumulation of epigenetic events in those cells is associated with a high risk of relapse, independently of MYCN amplification.
Authors: Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245
Authors: Paula Lázcoz; Jorge Muñoz; Manuel Nistal; Angel Pestaña; Ignacio J Encío; Javier S Castresana Journal: Cancer Genet Cytogenet Date: 2007-04-01
Authors: M Josefa Bello; M Eva Alonso; Cinthia Amiñoso; Nilson P Anselmo; Dolores Arjona; Pilar Gonzalez-Gomez; Isabel Lopez-Marin; Jose M de Campos; Manuel Gutierrez; Alberto Isla; M Elena Kusak; Luis Lassaletta; Jose L Sarasa; Jesus Vaquero; Cacilda Casartelli; Juan A Rey Journal: Mutat Res Date: 2004-10-04 Impact factor: 2.433
Authors: L Jubierre; A Soriano; L Planells-Ferrer; L París-Coderch; S P Tenbaum; O A Romero; R S Moubarak; A Almazán-Moga; C Molist; J Roma; S Navarro; R Noguera; M Sánchez-Céspedes; J X Comella; H G Palmer; J Sánchez de Toledo; S Gallego; M F Segura Journal: Oncogene Date: 2016-03-21 Impact factor: 9.867
Authors: Maja Šutić; Antje Motzek; Gordana Bubanović; Matthias Linke; Ivan Sabol; Oliver Vugrek; Petar Ozretić; Luka Brčić; Sven Seiwerth; Željko Debeljak; Antonija Jakovčević; Zoran Janevski; Dinko Stančić-Rokotov; Andrea Vukić-Dugac; Marko Jakopović; Miroslav Samaržija; Ulrich Zechner; Jelena Knežević Journal: Transl Lung Cancer Res Date: 2019-12
Authors: C Athena Aktipis; Virginia S Y Kwan; Kathryn A Johnson; Steven L Neuberg; Carlo C Maley Journal: PLoS One Date: 2011-11-17 Impact factor: 3.240
Authors: Anneleen Decock; Maté Ongenaert; Jasmien Hoebeeck; Katleen De Preter; Gert Van Peer; Wim Van Criekinge; Ruth Ladenstein; Johannes H Schulte; Rosa Noguera; Raymond L Stallings; An Van Damme; Geneviève Laureys; Joëlle Vermeulen; Tom Van Maerken; Frank Speleman; Jo Vandesompele Journal: Genome Biol Date: 2012-10-03 Impact factor: 13.583
Authors: Yania Yáñez; Elena Grau; Virginia C Rodríguez-Cortez; David Hervás; Enrique Vidal; Rosa Noguera; Miguel Hernández; Vanessa Segura; Adela Cañete; Ana Conesa; Jaime Font de Mora; Victoria Castel Journal: Clin Epigenetics Date: 2015-02-27 Impact factor: 6.551